| |
Gene
|
Gene expression changes (average FC)a
|
|---|
| |
CPXV
|
MPXV
|
VACV
|
|---|
|
MAPK activity
|
DUSP5
|
6.6
|
4.9
|
3.6
|
|
DUSP6
|
8.1
|
9.5
|
5.2
|
|
EGR1
|
14.3
|
30.8
|
98.6
|
|
EGR2
|
2.6
|
5.1
|
4.2
|
|
IL4R
|
6.2
|
5.8
|
2.9
|
|
LIF
|
9.7
|
12.6
|
4.6
|
|
SPRY1
|
12.7
|
n.s.b
|
n.s.b
|
|
SPRY2
|
7.7
|
7.1
|
7.0
|
|
SPRY4
|
20.8
|
30.1
|
11.8
|
|
SPRED1
|
2.8/3.7c
|
2.9/3.0c
|
2.2/2.2c
|
|
SPRED2
|
2.0
|
2.3
|
2.8/7.8c
|
|
both
|
CBLB
|
−2.7
|
−3.4
|
−2.5
|
|
ErbB pathway
|
AREG
|
10.2
|
8.3
|
4.8
|
|
EREG
|
4.4/6.7c
|
7.0/10.3c
|
2.9/3.0c
|
|
HBEGF
|
4.0/5.4c
|
2.3/2.6c
|
2.1/2.8c
|
|
PRKCB
|
−4.9
|
−3.4
|
−2.4
|
- a Cluster and pathway analysis of the 87 non-histone transcripts that were affected by all OPV tested revealed a statistically significant overrepresentation of genes involved in inactivation of mitogen-activated protein kinase (MAPK) activity and growth factor signalling. Shown are gene expression changes of the identified genes at 6 h post infection in CPXV-, VACV- or MPXV-infected cells in comparison to mock-infected cells as average fold change (FC) values.
- b Values that did not meet the analysis cut-off of an average FC ≥2.0 and p ≤0.05 are designated n.s. (not significant).
- c Two values separated by a slash designate values obtained from two different probes on the microarray.
